High resolution detection of BCR-ABL gene fusion. The BCR-ABL fusion gene is formed when pieces of chromosomes 9 and 22 break off and trade places. The ABL gene from chromosome 9 joins to the BCR gene on chromosome 22, to form the BCR-ABL fusion gene. The changed chromosome 22 with the fusion gene on it is called the Philadelphia chromosome, which is found in most patients with chronic myelogenous Leukaemia (CML), and in some patients with acute lymphoblastic Leukaemia (ALL) or acute myelogenous leukaemia (AML).
The SureSeq™ BCR-ABL translocations are detected by baiting the BCR gene but not ABL. If the translocation has taken place, the sequence depth drops off in BCR, and is picked up by SureSeq Interpret, in the ABL region, despite not being baited. OGT is currently working on other known translocations to add to our panel design capability.